Psyence Biomedical CEO says 2025 was a ‘turning point’ for company

Psyence Biomedical (PBM) released a year-end Letter from CEO Jody Aufrichtig, summarizing the Company’s 2025 achievements and outlining its strategic vision for 2026. In his year-end letter to shareholders, Aufrichtig described 2025 as a “turning point” in which Psyence BioMed delivered clinical execution, strengthened global manufacturing ties, and positioned itself at the forefront of the convergence between nature-derived psychedelic therapeutics and longevity science. WWe recruited and dosed our first patients in a Phase IIb study. Through a further investment in PsyLabs we secured our psychedelic compound supply chain and became the only listed company with an investment in sustainable Ibogaine at source in Africa. We commenced studies in the exciting field of Longevity and ended the year debt free with over $9 million in cash reserves.” Psyence BioMed advanced its Phase IIb clinical trial evaluating psilocybin-assisted psychotherapy for the treatment of Adjustment Disorder in palliative care. Multiple patients were dosed across several Australian clinical sites, supported by a partnership with Southern Star Research, one of Australia’s leading clinical research organisations. The Company strengthened its vertical integration through a multi-million-dollar follow-on investment in PsyLabs, securing GMP compliant nature-derived psilocybin and ibogaine supply for current and future programs. Psyence BioMed also announced a breakthrough in high purity ibogaine production, reinforcing its manufacturing advantage. Aufrichtig noted the importance of the Australian Therapeutic Goods Administration’s public consultation on psilocybin-assisted therapy for existential distress in patients with life-limiting illness – a development closely aligned with the Company’s clinical trial. If approved, the amendment would enable supervised access through the Authorised Prescriber framework and expand the eligible prescriber group to include palliative-care specialists. The Company plans to accelerate enrollment in its Phase IIb clinical trial, expand its manufacturing footprint, pursue additional longevity-focused indications, and evaluate strategic partnership opportunities throughout 2026.